A randomized controlled trial exploring the role of etanercept as a treatment for uveitis found no difference in outcome between etanercept and placebo-treated patients [10], suggesting that among children with uveitis, etanercept is not an effective treatment, unlike other drugs within the TNF inhibitor class, including adalimumab via a randomized controlled trial (SYCAMORE) [11] and infliximab through a case series [12]. The gene discussed is TNF; the disease is uveitis.